There has been a lot of attention in recent years on the outsourcing of pharmaceutical research and manufacturing to India. While domestic pharma majors may be the beneficiaries of this trend, the original giants of outsourcing are not lagging far behind. IT behemoths like TCS and Wipro are grabbing a piece of the pharma outsourcing pie by getting involved in clinical data management. TCS recently secured a deal with Eli Lilly, which includes the establishment of a facility in Noida. Other pharma companies too have outsourced clinical data management operations to India including Pfizer, GlaxoSmithKline, Novo Nordisk and Wyeth.
And then this on biomedical opportunities in China:
There are over 2,000 Chinese-foreign joint ventures in the biomedical sector, including major players like Roche (RHHBY), Novartis (NVS), GSK (GSK), Pfizer (PFE), Medtronic (MDT), Becton Dickinson (BDX) and Inverness Medical (IMA), just to name a few. Most are significantly expanding their operations and are investing heavily in research and development to move beyond just manufacturing and distribution. China is encouraging and even subsidizing this migration, as it recognizes that to sustain its incredible historic growth rate of 9% per year, it must move its economy toward R&D.
No comments:
Post a Comment